TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells.
Company profile
Website
Employees
Incorporated
Location
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
16 Aug 18
SC 14D9/A
Tender offer solicitation (amended)
31 Jul 18
6-K
Current report (foreign)
31 Jul 18
SC TO-T/A
Third party tender offer statement (amended)
31 Jul 18
SC 14D9/A
Tender offer solicitation (amended)
26 Jul 18
SC TO-T/A
Third party tender offer statement (amended)
26 Jul 18
6-K
Current report (foreign)
26 Jul 18
25
Voluntary exchange delisting
16 Jul 18
SC 14D9/A
Tender offer solicitation (amended)
13 Jul 18
6-K
Q&A in respect of Takeda’s intention to acquire TiGenix
13 Jul 18
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|